COMMUNIQUÉS West-GlobeNewswire

ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer’s Disease

06/11/2018 - 13:30

Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer TORONTO and CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences [...]

Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress

06/11/2018 - 13:30

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]

Kura Oncology to Participate in Two Upcoming Investor Conferences

06/11/2018 - 13:30

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy [...]

OpGen Completes Specimen Accrual and Testing in Acuitas® Clinical Verification Study

06/11/2018 - 13:30

Study evaluated potential utility in management of complicated urinary tract infections; Analysis and peer-reviewed manuscript preparation are underway GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. ( [...]

Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress

06/11/2018 - 13:30

PHILADELPHIA, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today [...]

Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss

06/11/2018 - 13:30

Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development [...]

Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance

06/11/2018 - 13:30

58% Revenue Growth Over Third Quarter 2017 Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the [...]

Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update

06/11/2018 - 13:30

Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with [...]

Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors

06/11/2018 - 13:05

DARTMOUTH, Nova Scotia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has appointed seasoned biopharmaceutical executive Markus [...]

AxoGen to Host Third Annual Analyst and Investor Day on November 19, 2018

06/11/2018 - 13:00

ALACHUA, Fla., Nov. 06, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced [...]

Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results

06/11/2018 - 13:00

BERKELEY HEIGHTS, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]

Microbix Exhibiting at MEDICA Trade Fair

06/11/2018 - 13:00

Showcasing Antigen and Quality Assessment Products TORONTO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix ® ), an innovator of biological products and technologies, announces that it [...]

G1 Therapeutics to Present at Investor Conferences in November 2018

06/11/2018 - 13:00

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will [...]

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

06/11/2018 - 13:00

THE WOODLANDS, Texas, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief [...]

Akcea Therapeutics to Present at Upcoming Investor Conferences

06/11/2018 - 13:00

BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare [...]

InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update

06/11/2018 - 13:00

Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, [...]

RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018

06/11/2018 - 13:00

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]

Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13

06/11/2018 - 13:00

LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of [...]

Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

06/11/2018 - 13:00

- New Drug Application for CONTEPO ™ submitted to FDA in October 2018 - - Company preparing for potential commercialization of two, first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United [...]